CrystalsFirst's MAGNET platform overcomes current limitations of small molecule drug discovery. Our proprietary structural biology technology detects molecular magnets and generative AI/Machine Learning identifies novel molecules and druggable binding pockets for difficult targets. Our MAGNET Platform is a unique and powerful approach to unlock chemical matter. It integrates the “crystal structure first” strategy, large-scale computational modelling, generative AI and medicinal chemistry. Starting with crystal structures as the first step in drug discovery, we also gain valuable insights into target interactions, enabling rational design from the beginning. Building block chemistry provides rapid access to diverse chemical scaffolds, facilitating hit expansion, scaffold hopping, and efficient compound generation. Computational modelling and machine learning aid in predicting compound properties and optimizing lead candidates. The synergistic combination of these elements in the MAGNET Platform accelerates the discovery process and increases the likelihood of finding innovative and effective therapeutic compounds.